By Adria Calatayud Germany's Merck KGaA has entered into a partnership to license a cancer drug developed by China's Jiangsu Hengrui Pharmaceuticals for up.
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
By Adria Calatayud Germany s Merck KGaA has entered into a partnership to license a cancer drug developed by China s Jiangsu Hengrui Pharmaceuticals for up to 1.4 billion euros . Merck.
Germany's Merck KGaA on Monday said it struck a collaboration deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to widen Merck's work in an area known as "DNA damage response" drugs. In a statement on Monday, diversified group Merck said it agreed to pay Hengrui 160 million euros ($169 million) upfront. The deal could be worth up to 1.4 billion euros when including payments contingent on development and commercial achievement as well as royalties on sales.
A Hengrui drug that interferes with a cancer cell’s DNA damage response is heading to Merck KGaA for €160 million up front and up to €1.4 billion tied to milestones. The deal also gives the German company an option to license a Hengrui antibody drug conjugate.